NEWS RELEASE - PRESSEMITTEILUNG

Acino appoints Kalle Känd as Head of Emerging Markets & Strategy and Konstantin Bakaykin as Head of Business Development

Aesch, May 7, 2014, 17.30 hrs - Acino announced today the appointment of two new leaders to head up its commercial operations:

Kalle Känd has been appointed as Head of Emerging Markets & Strategy and a Member of Group Management. He joins Acino from Takeda Pharmaceuticals International GmbH, where he has been responsible for strategy and emerging markets. Over his 20-year career in pharmaceuticals he held several roles of increasing responsibility in strategic planning, alliance management, marketing, sales, as country manager and managing director on behalf of several healthcare companies (including former Nycomed) in Russia, Denmark, and the Baltic States. He is a graduate Doctor of Medicine and also holds a degree in economics and business administration from the University of Tartu, Estonia.

Kalle Känd succeeds Ruud van Anraat, who decided to leave the company to pursue
career opportunities outside Acino. The company thanks Ruud van Anraat for his important contributions at Acino, especially with regard to the international business expansion, and wishes him the very best for the future.

Konstantin V. Bakaykin has been named Head of Business Development and a Member of Group Management. Most recently he served in a similar function at Takeda Pharmaceuticals International GmbH. He can look back on a long and successful career in healthcare and has held leadership positions in business development, market intelligence, marketing, and as franchise and promotions manager for multinational companies. He studied at the Geological Academy of the Russian Federation in Moscow, Russia.

Håkan Björklund, Chairman of Acino Holding AG, said: "With Kalle Känd and Konstantin Bakaykin, our company has been able to attract two strong and experienced leaders. Their broad expertise and proven managerial capabilities will be invaluable in accelerating the growth of our international business and strengthening our competitive market positions. They also share a vision to drive a high-performing culture. We are delighted that they are joining our company."
Konstantin Bakaykin and Kalle Känd will both join the Group on May 16, 2014, and will report to Jostein Davidsen, Acino's new CEO, who will take up his new role the same day.

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Aesch BL.

On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Contact

Robert Schmid

Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com

Acino Holding AG

Page 2 / 2

Dornacherstrasse 114

CH-4147 Aesch

Telefon +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

distributed by